The SBIR/STTR program that funded early-stage biotech translation expired in October 2025, eliminating $4B+ in annual non-dilutive funding for pre-revenue life science startups

The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs -- which provided over $4 billion annually to more than 4,000 companies for translating academic discoveries into commercial products -- lost their congressional authorization on October 1, 2025, when the new fiscal year began without a reauthorization agreement. On November 17, 2025, NIH released a notice that the programs had expired 'effective immediately,' cutting off the primary non-dilutive funding source for early-stage biotech companies bridging the 'valley of death' between academic research and venture-fundable clinical programs. Why it matters: 38% of seed-stage biotech companies had planned to make non-dilutive funding a core strategy in 2024-2025, so these companies now face an existential funding gap at precisely the stage where venture capital is least available (pre-IND, pre-clinical proof of concept), so academic discoveries that would have been translated into therapeutic candidates through SBIR Phase I/II grants will stall in university labs, so the pipeline of innovative small-molecule, biologic, and diagnostic programs from small companies will contract, so breakthrough therapies that typically originate in small biotech (which account for ~65% of FDA novel drug approvals) will be delayed or lost entirely. The structural root cause is that SBIR/STTR reauthorization became entangled in broader congressional disputes about program structure, set-aside percentages, and foreign ownership restrictions, and no champion in Congress prioritized biotech translation funding sufficiently to force a standalone reauthorization before the expiration deadline.